A detailed history of Northern Trust Corp transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 107,850 shares of UNCY stock, worth $64,710. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,850
Previous 58,181 85.37%
Holding current value
$64,710
Previous $45,000 35.56%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025

BUY
$0.5 - $0.8 $24,834 - $39,735
49,669 Added 85.37%
107,850 $61,000
Q4 2024

Feb 14, 2025

BUY
$0.35 - $0.81 $11,964 - $27,688
34,183 Added 142.44%
58,181 $45,000
Q1 2024

May 14, 2024

BUY
$0.83 - $1.79 $19,918 - $42,956
23,998 New
23,998 $33,000

Others Institutions Holding UNCY

About Unicycive Therapeutics, Inc.


  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $9.03M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.